MedTrace Logo

Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis

NCT04043897 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-04-15

No results posted yet for this study

Summary

This is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.

Conditions

  • Microscopic Colitis

Interventions

DRUG

Rifaximin 550mg

Rifaximin 550mg

Sponsors & Collaborators

  • Eugene F Yen, MD

    lead OTHER

Principal Investigators

  • Eugene Yen, MD · Endeavor Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-29
Primary Completion
2021-12-31
Completion
2021-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04043897 on ClinicalTrials.gov